METASTATIC RENAL CELL CARCINOMA

This study tests whether a combination of three drugs (sasanlimab, palbociclib, and axitinib) can shrink tumors in people with advanced kidney cancer that has spread. About 25 adults with clear cell or translocation renal cell carcinoma will receive the drugs and be monitored for…

This study is for people with kidney cancer that has spread and is starting to grow again in just a few places while on standard drug therapy. Instead of switching to a new drug right away, doctors will use precise, high-dose radiation (stereotactic radiotherapy) to target only t…

This study tests the drug olaparib (a pill) in 20 people with advanced kidney cancer that has spread. To join, your tumor must have a specific gene mutation (like BAP-1 or BRCA). The goal is to see if the drug can shrink or stop tumor growth for at least 6 months. Participants mu…

This study is for people with advanced kidney cancer that has spread and cannot be removed by surgery. It tests whether adding a precise, high-dose form of radiation (SABR) to the main tumor, alongside standard immunotherapy drugs, can better control the cancer and delay its grow…

This early-phase study tests a wearable device that creates low-intensity electric fields to disrupt cancer cell growth, combined with standard drugs (cabozantinib or nab-paclitaxel plus atezolizumab). About 43 adults with advanced solid tumors in the abdomen or chest that have s…

This study tests whether precisely targeted radiation (SBRT) can stop or slow the growth of a few new cancer spots in patients with metastatic kidney cancer who are already on immunotherapy. About 30 adults will receive radiation to up to 5 growing tumors while continuing their c…

This study is for people with kidney cancer that has spread to other parts of the body. It compares standard immunotherapy drugs (like nivolumab and axitinib) alone versus the same drugs plus surgery to remove the affected kidney. The goal is to see if adding surgery helps patien…

This study tests a personalized vaccine made from a patient's own tumor proteins, combined with the immunotherapy drug pembrolizumab, for people with advanced solid tumors (like breast, lung, or skin cancer). The goal is to see if the combination is safe and helps the immune syst…

This study tests a different way of taking the drug cabozantinib to see if it causes fewer side effects while still controlling cancer growth. It includes adults with advanced kidney cancer or neuroendocrine tumors. The goal is to find a dose schedule that patients can tolerate b…

This study tests whether combining two drugs, abemaciclib and cabozantinib, is safe and works for people with advanced kidney cancer that has not responded to immunotherapy. About 43 adults with clear cell or translocation-associated kidney cancer will take part. Researchers will…

This study tests a new medicine, PF-08634404, in adults with advanced kidney cancer that has spread. The goal is to see if it is safe and can shrink tumors when given alone or with other cancer drugs. About 224 participants will receive the drug through an IV. This is an early-ph…

This study tests whether combining two drugs, pembrolizumab and aldesleukin, can shrink tumors in people with advanced melanoma or kidney cancer that has not responded to standard treatments. Participants receive the drugs through an IV during two short hospital stays, followed b…

This study tests a new drug called zanzalintinib, alone or with an immunotherapy (nivolumab), in people with advanced kidney cancer that got worse after standard first treatment. About 70 adults will take part. The goal is to see if the combination can shrink tumors or slow the d…

This study tests whether weekly digital symptom reports from patients with advanced kidney cancer can help doctors make timely adjustments to their treatment with cabozantinib and nivolumab. About 83 adults starting this combination therapy will use a digital platform to report s…

This early-stage trial explores whether a ketogenic (low-carb, high-fat) diet can help standard immunotherapy drugs work better in people with advanced melanoma or kidney cancer. About 60 adults will follow the diet while receiving treatment, and researchers will monitor safety a…

This study compares two types of radiation therapy for people whose cancer has spread to the brain. One group gets a single high dose of radiation, while the other gets three smaller doses over several days. The goal is to see if the three-dose approach works better at controllin…

This study is testing whether getting immunotherapy in the morning or the afternoon makes it work better for people with advanced or metastatic solid tumors like lung, kidney, or skin cancer. Researchers think the body's internal clock might affect how the immune system responds.…

This study tests whether adding cryoablation (freezing cancer cells) to standard radiation therapy provides better pain relief for people with cancer that has spread to the bones. About 40 adults with certain advanced cancers (like prostate, kidney, or colorectal) will be enrolle…

This study tests a small implantable device that releases tiny amounts of 19 different cancer drugs directly into a kidney tumor. The goal is to see if the device is safe and can help doctors figure out which drug works best for each patient. About 20 adults with kidney cancer wh…